CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 246 enrolled
Drug / intervention
GDPbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04217863
NCT04217863N/ACompleted

Effects of the Guided Disclosure Protocol on Post-Traumatic Growth: A Randomized Control Trial Designed to Observe Psychophysiological Alterations in Traumatic Stress Subjects

University of Karachi·interventional·Posted Jan 6, 2020·Updated Aug 11, 2021

In Brief

A clinical study evaluating GDP for Traumatic Stress, Post-Traumatic Growth. Completed, enrolled 246 participants across 1 site.

Detailed Summary

This Multicenter study is planned to investigate the effectiveness of the guided disclosure protocol for the promotion of post-traumatic growth (PTG), in the traumatic stress subjects and to determine whether PTG is associated with psychophysiological alterations i.e. (C-Reactive Protein, Brain Derived Neurotropic Factor, Interlukin-6, Cortisol, Heart Rate Variability and brain waves). Study subjects meeting eligibility criteria will be randomized into two groups. Guided disclosure protocol (GDP) will be used as intervention vs the control. Blinded treatment will be provided and the subjects will be made to complete study questionnaires (Screening, Traumatic Stress Scale SSS, Trauma Symptom Checklist, Post-traumatic growth Inventory) at baseline and at post-intervention (3-months later).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPakistan

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJan 6, 2020
Enrollment StartDec 2, 2019
Primary CompletionAug 10, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.5 years ago

Interventions

GDPbehavioral

Guided Disclosure Protocol